Avid Bioservices Inc (CDMO)

[entdoc]

Friday wrap. Apples and oranges. Compare treatment of 2 small groups of advanced pancreatic cancer patients. Tie the hands of one treament (Bavituximab) behind its back in a survival contest by assigning sicker patients to the Bavi group, and then compare median months of survival. More than 100% improvement in response rate with Bavi over standard of care (SOC), and 10% improvement in mean survival. Collosal fail(not). Stock tanks (yet again). CEO Stephen King says in advance (read my lips), "look for a huge disconnect" in the data, and then, as an aside when disclosing PII trial results, "very interesting data in a subset [of the current survivors in the Bavi treatment group]...Can't disclose more, mind you, although it is logically an overpoweringly important fact to stockholders, data probably known by stoholder biggies and other pharma insiders--potential financiers and partners for PPHM anti-PS platform for cancer treatment. Hardly a blowout with big holders increasing their investment in PPHM, and huge China-India-Russia interest. Little PPHM is going global. Hang on kids...and have a good weekend.